Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
44M people world wide
...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included.

44M people world wide


-
...TBI increases risk of dementia by as much as two-fold
  
44M people world wide
44M People World Wide

...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included...

Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

 

        NEWS AND EVENTS 2013 - 2015

 


          September 15, 2015: ALSP Inc. is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA)
           with Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, to conduct traumatic brain injury (TBI) research on the Company's
           primary therapeutic target, cathepsin B, and the use of the Company's compounds to effect TBI outcomes in animal models. Read More...
 

                                                                                                               

June 29, 2015: The poster entitled "Brain cathepsin B is elevated following trauma in both mild-closed and severe-penetrating traumatic brain injury models", was presented at the National Society of Neurotrauma, Santa Fe, NM, by researchers at the Walter Reed Army Institute of Research, Silver Spring, MD, and co-authored by Drs. Greg Hook, VP ALSP Research, and Vivian Hook, Professor, UCSD, and ALSP Advisor Read More...

                                                                                                               

February 2, 2015: ALSP Inc. announced today that it has signed a license agreement with Columbia University to develop a series of proprietary compounds that are related to its lead clinical drug candidate, ALP-496, in the field of neurodegenerative disease. The compounds were identified by a team of investigators led by Dr. Ottavio Arancio, Associate Professor of Pathology and Cell Biology at Columbia University, and Dr. Gregory Thatcher, the Hans Valteich Chair of Medicinal Chemistry , College of Pharmacy, and Director of UICentre (drug discovery @ UIC) at the University of Illinois at Chicago Read More...


July 13, 2014: Drs. Greg Hook, VP Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Advisor, presented at the American Alzheimer's International Conference (AAIC) in Copenhagen, Denmark July 12-17. The below abstracts are available:


Cysteine Protease Inhibitor, E64d, of Cathepsin B Reduces pGlu-Abeta and Abeta, and Improves Memory Deficits in the APPLon Mouse Model of AD

Cathepsin B Knockout Reduces pGlu-Ab and Ab, and Improves Memory Deficits, in the APPLon Mouse Model of AD



July 1, 2014: At national Neurotrauma Symposium, San Francisco, CA, Drs. Greg Hook, VP Research, ALSP and Vivian Hook, Professsor UCSD and ALSP Advisor, made a poster presentation:


>The Cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for TBI. Please read Abstract






representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.


>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

***